Cargando…
Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
Fragile X syndrome (FXS) is the leading known cause of inherited intellectual disability and autism spectrum disorder. It is caused by a mutation of the fragile X mental retardation 1 (FMR1) gene, resulting in a deficit of fragile X mental retardation protein (FMRP). The clinical presentation of FXS...
Autores principales: | Lee, Anna W., Ventola, Pamela, Budimirovic, Dejan, Berry-Kravis, Elizabeth, Visootsak, Jeannie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315847/ https://www.ncbi.nlm.nih.gov/pubmed/30563047 http://dx.doi.org/10.3390/brainsci8120214 |
Ejemplares similares
-
Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017) -
Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study
por: Budimirovic, Dejan B., et al.
Publicado: (2021) -
Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018) -
Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
por: Luu, Skylar, et al.
Publicado: (2020) -
Targeted treatments for fragile X syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2011)